Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis.
about
hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicineStem cell-derived liver cells for drug testing and disease modelingA protocol for the identification and validation of novel genetic causes of kidney diseaseEvaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like Cells.New markers for tracking endoderm induction and hepatocyte differentiation from human pluripotent stem cells.Genome Editing of the CYP1A1 Locus in iPSCs as a Platform to Map AHR Expression throughout Human Development.ALS-linked mutations enlarge TDP-43-enriched neuronal RNA granules in the dendritic arbor.Potential of human induced pluripotent stem cells in studies of liver disease.Pluripotent stem cells in disease modelling and drug discovery.A Paracrine Mechanism Accelerating Expansion of Human Induced Pluripotent Stem Cell-Derived Hepatic Progenitor-Like Cells.Hepatocyte-like cells derived from induced pluripotent stem cells.Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes.Emergence of a stage-dependent human liver disease signature with directed differentiation of alpha-1 antitrypsin-deficient iPS cells.Lipidomic profiling of patient-specific iPSC-derived hepatocyte-like cells.Induced pluripotent stem cells model personalized variations in liver disease resulting from α1-antitrypsin deficiency.7q11.23 dosage-dependent dysregulation in human pluripotent stem cells affects transcriptional programs in disease-relevant lineages.A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a Potential Treatment for Hypercholesterolemia.
P2860
Q26751506-F3ADE366-6F85-421B-AAED-DAA1B65AC838Q27012605-65E26AC6-B566-40B1-A596-C8596D28248EQ35776875-1F385F7D-FD8D-4427-86CC-2D1DFC40349BQ36120100-2319E474-793D-409D-889C-80CFD3AD8397Q36398923-3A8471D9-01F3-4ED5-BBF6-DBBBDAD1B296Q36829190-B17B1C85-F8CA-46C2-85BD-BA67AB4AF744Q37650180-9DD6E11E-8F33-40B7-8F44-7D3617B20FA9Q38287145-CCD1F86F-33B8-4802-A8DC-611EF8A82A08Q38714328-05B356D2-568B-435C-800F-8BAFDBF049B6Q38895292-92EFC929-82C7-43C5-93E2-F190A2285A37Q38929094-46341A88-E58B-4FAA-8134-9F8269DAEFBDQ39345477-F5349796-85F2-4D70-A052-F873E498F236Q40843065-55C2506E-0644-4580-9388-1E50E210F0D5Q41664781-3DF1C8AE-6588-4FC8-9A25-503902DC737EQ41674444-B739DE21-48D9-4157-85BD-1F091453640AQ48246014-036316EC-EC51-43FE-9520-BC5F8CDA8FBAQ51067287-51F110B2-0BD7-4CD3-A38A-B5C16930FD35
P2860
Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Induced pluripotent stem cell ...... ary transthyretin amyloidosis.
@en
Induced pluripotent stem cell ...... ary transthyretin amyloidosis.
@nl
type
label
Induced pluripotent stem cell ...... ary transthyretin amyloidosis.
@en
Induced pluripotent stem cell ...... ary transthyretin amyloidosis.
@nl
prefLabel
Induced pluripotent stem cell ...... ary transthyretin amyloidosis.
@en
Induced pluripotent stem cell ...... ary transthyretin amyloidosis.
@nl
P2093
P2860
P50
P1433
P1476
Induced pluripotent stem cell ...... tary transthyretin amyloidosis
@en
P2093
Benjamin Wolozin
Darrell N Kotton
David C Seldin
George J Murphy
Gustavo Mostoslavsky
John L Berk
Joseph C Genereux
Shirley K Nah
Whitney Reid
P2860
P304
P356
10.1016/J.STEMCR.2013.10.003
P577
2013-10-31T00:00:00Z